EC
AIMT

EcoR1 Capital’s Aimmune Therapeutics AIMT Stock Holding History

EcoR1 Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-521,366
Closed -$7.07M – 40
2016
Q1 		$7.07M Buy
+521,366
New +$8.13M 2.47% 16

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

EcoR1 Capital's AIMT Position: Q2 2016 in Review

EcoR1 Capital sold out of Aimmune Therapeutics (AIMT) in Q2 2016, closing a stake of 521,366 shares — an estimated $7.07M sold.

EcoR1 Capital first reported a position in AIMT in Q1 2016 and held it in 1 quarter. The position peaked at $7.07M in Q1 2016. 74 funds tracked by Wall St. Rank hold AIMT as of Q2 2016.

  • EcoR1 Capital reported no remaining Aimmune Therapeutics position as of Q2 2016 after selling out during the quarter.
  • EcoR1 Capital sold 521,366 Aimmune Therapeutics shares in Q2 2016, an estimated $7.07M.
  • EcoR1 Capital first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 1 quarter.
  • EcoR1 Capital's Aimmune Therapeutics position peaked at $7.07M in Q1 2016.
  • 74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2016.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.